| ¿µ¹® | half-life | ÇÑ±Û | ¹Ý°¨±â |
|---|---|---|---|
| ¼³¸í | ¾î¶² ¹°ÁúÀÌ ¿ÜºÎÀû ¿äÀÎ, ¶Ç´Â ³»ºÎÀû ¿äÀο¡ ÀÇÇØ¼ ºÐÇØµÉ °æ¿ì¿¡ ±× ¹°ÁúÀÇ ¿ø·¡ÀÇ ¾ç¿¡¼ ¹ÝÀÌ µÇ´Â µ¥ °É¸®´Â ½Ã°£. |
||
| ¿µ¹® | five-year survival rate | ÇÑ±Û | ¿À³â»ýÁ¸À² |
|---|---|---|---|
| ¼³¸í | 1. µ¿ÀÏ Áúº´ÀÇ Áø´Ü ȤÀº Ä¡·á ÈÄ, 5³âÀÌ °æ°ú µÈ µÚÀÇ »ýÁ¸ÀÚ¼öÀÇ Ç¥Çö. 2. ¾ÏÀÇ Áø´Ü ¶Ç´Â Ä¡·á µÚ¿¡ °Ë»ç¸¦ ¹Ýº¹ÇÏ¿© 5³â µ¿¾È »ì¾Æ ÀÖ´Â »ç¶÷ÀÇ ¹éºÐÀ². Ä¡·á ÈÄ 5³â µ¿¾È »ýÁ¸Çϸé ÀÏ´Ü Ä¡À¯µÈ °ÍÀ¸·Î °£ÁÖÇÑ´Ù. |
||
| ¿µ¹® | coagulation time | ÇÑ±Û | ÀÀ°í½Ã°£ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò¶õ ¹°ÁúÀº ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. Ç÷¾×ÀÀ°í´Â ´ÙÀ½°ú °°Àº 3´Ü°è·Î ÀÌ·ç¾îÁø´Ù. ù¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼ prothrombin activator¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ prothrombin activator¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ Ç÷¾×¼Ó¿¡ ÀÖ´Â ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ÀÀ°íÀÛ¿ëÀº Å©°Ô 2°¡Áö·Î ³ª´µ´Âµ¥, ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ°¡ ±×°ÍÀÌ´Ù. ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ´Â °¢±â º°°³·Î ÀÛ¿ëÇÏÁö¸¸, °á±¹Àº ¸¶Áö¸· °úÁ¤¿¡¼ Çϳª·Î ¸¸³ª¼ ¼¶À¯¼Ò¿øÀ» ¼¶À¯¼Ò(ÀÀ°íÀÛ¿ëÀÇ ¸¶Áö¸· ´Ü°è¿¡ »ý¼ºµÇ¸ç ´Ü´ÜÇϰí Ç®¸®Áö ¾Ê´Â ¸ÅµìÀ» Çü¼ºÇÏ¿© ÁöÇ÷ÀÛ¿ëÀ» ¿Ï¼ºÇÑ´Ù)À¸·Î ¸¸µé¾î ÀÀ°íÀÛ¿ëÀ» ³ªÅ¸³½´Ù. |
||
| ¿µ¹® | bleeding time | ÇÑ±Û | ÃâÇ÷½Ã°£ |
|---|---|---|---|
| ¼³¸í | ¸ö¿¡ »óó°¡ ³ª¼ ÃâÇ÷ÀÌ ÀÖ¾úÀ» °æ¿ì¿¡ Çǰ¡ ¸Ü´Âµ¥ ±îÁö °É¸®´Â ½Ã°£À» ÃâÇ÷½Ã°£À̶ó°í ÇÑ´Ù. »ç¶÷ÀÇ ¸ö¿¡ »óó°¡ ³ª¼ ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡ À̰ÍÀ» ¸·°í ÇǸ¦ ´õÀÌ»ó ³ªÁö ¾Ê°Ô ÇÏ´Â °ÍÀ» ÁöÇ÷À̶ó°í ÇÑ´Ù. ÁöÇ÷ÀÇ °úÁ¤¿¡´Â Å©°Ô µÎ °¡Áö ´Ü°è°¡ ÀÖ´Ù. ù¹øÂ° ´Ü°è´Â Ç÷¼ÒÆÇµéÀÌ »óó°¡ ³ª¼ ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¸¦ ¸·´Â °ÍÀÌ´Ù. ÀÌ·¸°Ô ÇÏ¸é ¿ì¼± Ç÷°üÀÇ ¼Õ»óºÎÀ§·ÎºÎÅÍ Çǰ¡ ³ª¿À´Â °ÍÀ» ¸·À» ¼ö°¡ ÀÖ´Ù. ´ÙÀ½ÀÇ ´Ü°è´Â »óó¸¦ ¸·°í ÀÖ´Â Ç÷¼ÒÆÇÀ§¿¡ ¿©·¯ °¡Áö ¹°ÁúµéÀÌ ÀÛ¿ëÇØ¼ ´õ¿í ´Ü´ÜÇÏ°Ô ÇÏ¿© »óó°¡ ³ Ç÷°ü¿¡¼ Çǰ¡ »õ´Â °ÍÀ» ¿µ±¸È÷ ¸·´Â °ÍÀÌ´Ù. ½±°Ô ¸»Çϸé Ç÷¼ÒÆÇÀº º®µ¹¿¡ ÇØ´çÇÏ´Â °ÍÀÌ°í µÎ¹øÂ° °úÁ¤¿¡ Âü¿©ÇÏ´Â ¹°ÁúµéÀº ½Ã¸àÆ®¿¡ ÇØ´çÇÏ´Â °ÍÀÌ´Ù. ÀÌ µÎ °úÁ¤ÀÌ ¿ÏÀüÇÒ °æ¿ì¿¡ ÁöÇ÷ÀÌ ¼øÁ¶·Ó°Ô ÀϾÙ. ÃâÇ÷½Ã°£Àº À§¿¡¼ ¼³¸íÇÑ ÁöÇ÷ÀÇ µÎ°¡Áö °úÁ¤ Áß¿¡¼ ù¹øÂ° °úÁ¤¿¡ ÀÇÇØ¼¸¸ ¿µÇâÀ» ¹Þ´Â´Ù. Áï ¼Õ»óµÈ Ç÷°üÀ» ¸·¾ÆÁÖ´Â º®µ¹¿¡ ÇØ´çÇÏ´Â Ç÷¼ÒÆÇÀÇ ±â´É¸¸ Á¤»óÀÏ °æ¿ì¿¡ ÃâÇ÷½Ã°£Àº Á¤»óÀ¸·Î ³ª¿Â´Ù. ¸¸¾à Ç÷¼ÒÆÇÀÇ ±â´É¿¡ ÀÌ»óÀÌ ÀÖ´Â °æ¿ì¿¡´Â ÀÚ¿¬È÷ ÃâÇ÷½Ã°£ÀÌ ±æ¾îÁø´Ù. |
||
| ¿µ¹® | prothrombin time | ÇÑ±Û | ÇÁ·ÎÆ®·Òºó½Ã°£ |
|---|---|---|---|
| ¼³¸í | ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼ ÇÕ¼ºµÇ´Â ºñŸ¹Î K ÀÇÁ¸¼º ÀÀ°í´Ü¹éÁúÀÇ ÇϳªÀ̸ç, ÇÁ·ÎÆ®·Òºó½Ã°£Àº ¿ÜÀΰè ÀÀ°íȰ¼ºÀ» Á¾ÇÕÀûÀ¸·Î ƯÁ¤ÇÏ´Â °Ë»çÀÇ ÇϳªÀÌ´Ù. ÇǰËÇ÷Àå¿¡ Ä®½·À̿°ú Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾(Á¦III ÀÀ°íÀÎÀÚ)À» °¡ÇØ, ¼¶À¯¼Ò°¡ ³ªÅ¸³¯ ¶§±îÁöÀÇ ½Ã°£À¸ ÃøÁ¤ÇÑ´Ù. |
||
| ST | esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor... |
|---|---|
| PST | pancreatic suppression test; paroxysmal supraventricular tachycardia; penicillin, streptomycin, and ... |
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
| PTT | partial thromboplastin time; particle transport time; posterior tibial tendon (transfer); prothrombi... |
| CSR | central supply room; chart-stimulated recall [test]; Cheyne-Stokes respiration; continued stay revie... |
| HRT | Half-relaxation time |
|---|---|
| T 1/2 | Half-time |
| PHT | Pressure Half Time |
| t 1/2 | The half time |
| 1/2 RT | half-relaxation time |
| survival time | The period elapsing between the completion or institution of any procedure and death, the life-span of biologically or physically marked erythrocytes or other cells. (05 Mar 2000) |
|---|---|
| half and half nail | Division of the nail by a transverse line into a proximal dull white part and a distal pink or brown part; seen in uraemia. (05 Mar 2000) |
| half-time | The time, in a first-order chemical (or enzymic) reaction, for half of the substance (substrate) to be converted or to disappear. Compare: half-life. (05 Mar 2000) |
| median survival | <statistics> Median means the middle value. An equal number of people live longer as die earlier than the median. (16 Dec 1997) |
| cell survival | The span of viability of a cell characterised by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. (12 Dec 1998) |
| graft survival | <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. (12 Dec 1998) |
| survival | 1. A living or continuing longer than, or beyond the existence of, another person, thing, or event; an outliving. 2. Any habit, usage, or belief, remaining from ancient times, the origin of which is often unknown, or imperfectly known. "The close bearing of the doctrine of survival on the study of manners and customs." (Tylor) Survival of the fittest. <biology> See Natural selection, under Natural. Origin: From Survive. Source: Websters Dictionary (01 Mar 1998) |
| survival analysis | A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. (12 Dec 1998) |
| survival rate | The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. (12 Dec 1998) |
| disease-free survival | Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. (12 Dec 1998) |
| tissue survival | The span of viability of a tissue or an organ. (12 Dec 1998) |
| five year survival rate | The proportion of patients still alive five years after a diagnosis or form of treatment is completed. Usually applied to statistics of survival of cancer patients, since after five years, recurrences are much less likely to occur. (05 Mar 2000) |
| 5-year relative survival rate | <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer. (16 Dec 1997) |
| long-term survival | <oncology> Term used to describe the survival of leukaemia patients who have been disease free for prolonged periods of time, usually at least five years. The chance of disease returning (relapse) decreases with time. (13 Nov 1997) |
| biological half-life | <biochemistry, biology> This is the time required for one-half of the total amount of a particular substance in a biological system to be consumed or broken down by biological processes when the rate of removal is approximately exponential. Toxic chemicals with a long biological half-life (such as some pesticides) will tend to accumulate in the body and are, therefore, more likely to be harmful. A substance with a short biological half-life may still accumulate if a portion of it it becomes tightly bound to bone or other tissues, even if most of it is quickly cleared from the body. (21 Mar 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|